Systematic Review with Meta-analysis: the Effects of Immunomodulator or Biological Withdrawal from Mono- or Combination Therapy in Inflammatory Bowel Disease

Overview

Journal Aliment Pharmacol Ther

Specialties Gastroenterology
Pharmacology

Date 2020 Nov 29

PMID 33249621

Citations 7

Authors

Dora Dohos

Lilla Hanak

Zsolt Szakacs

Szabolcs Kiss

Andrea Parniczky

Balint Eross

Piroska Pazmany

Peter Hegyi

Patricia Sarlos

Affiliations

Soon will be listed here.

Abstract

Background: Withdrawal of treatment is a common therapeutic problem in patients with long-standing remission of inflammatory bowel disease.

Aims: To evaluate the relapse rate in patients with quiescent inflammatory bowel disease after cessation of biologic or immunomodulator therapy.

Methods: We searched five databases for studies evaluating disease relapse after withdrawal of monotherapy or a drug from combination therapy in Crohn's disease or ulcerative colitis. In meta-analysis, risk ratios (RR) were calculated with 95% confidence intervals (CI).

Results: Ten randomised controlled trials (587 patients) were included in the meta-analysis, and another nine studies in systematic review. Withdrawal of immunomodulator monotherapy resulted in a significantly higher risk of relapse within 24 months of follow-up compared to ongoing therapy in Crohn's disease, but not in ulcerative colitis (RR = 2.06, CI: 1.53-2.77 and RR = 1.39, CI: 0.85-2.26, respectively). Trial sequential analysis indicated that further studies with similar design are unlikely to change the significant association on relapse rates after withdrawing immunomodulator monotherapy in patients with Crohn's disease. Discontinuation of an immunomodulator from combination with biologics did not show a higher risk of relapse than continuation of both drugs (RR = 1.30, CI: 0.81-2.08). The relapse rate increased after withdrawal of biologic monotherapy, whereas contradictory results were observed after biologic withdrawal from combination regimens.

Conclusion: Continuing immunomodulator monotherapy should remain the preferred approach among patients with Crohn's disease, although long-term toxicity is a concern. Further randomised controlled trials are warranted in ulcerative colitis and on combination regimens including biologics.

Citing Articles

Discontinuation of therapy in inflammatory bowel disease: Current views.

Mestrovic A, Kumric M, Bozic J World J Clin Cases. 2024; 12(10):1718-1727.

PMID: 38660068 PMC: 11036474. DOI: 10.12998/wjcc.v12.i10.1718.

Multifunctional nanoparticle-mediated combining therapy for human diseases.

Li X, Peng X, Zoulikha M, Boafo G, Thapa Magar K, Ju Y Signal Transduct Target Ther. 2023; 9(1):1.

PMID: 38161204 PMC: 10758001. DOI: 10.1038/s41392-023-01668-1.

Evidence-Based Approach to the Discontinuation of Immunomodulators or Biologics in Inflammatory Bowel Disease.

Miyatani Y, Kobayashi T Digestion. 2022; 104(1):66-73.

PMID: 36450267 PMC: 9843544. DOI: 10.1159/000527776.

De-escalation of Therapy in Patients with Quiescent Inflammatory Bowel Disease.

Miyatani Y, Kobayashi T Gut Liver. 2022; 17(2):181-189.

PMID: 36375794 PMC: 10018304. DOI: 10.5009/gnl220070.

Combination Immunotherapy Use and Withdrawal in Pediatric Inflammatory Bowel Disease-A Review of the Evidence.

Meredith J, Henderson P, Wilson D, Russell R Front Pediatr. 2021; 9:708310.

PMID: 34621712 PMC: 8490777. DOI: 10.3389/fped.2021.708310.

References

DerSimonian R, Laird N . Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-88. DOI: 10.1016/0197-2456(86)90046-2. View

Bourrier A, Carrat F, Colombel J, Bouvier A, Abitbol V, Marteau P . Excess risk of urinary tract cancers in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Aliment Pharmacol Ther. 2015; 43(2):252-61. DOI: 10.1111/apt.13466. View

Best W, Becktel J, SINGLETON J, KERN Jr F . Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology. 1976; 70(3):439-44. View

Baert F, Drobne D, Gils A, Vande Casteele N, Hauenstein S, Singh S . Early trough levels and antibodies to infliximab predict safety and success of reinitiation of infliximab therapy. Clin Gastroenterol Hepatol. 2014; 12(9):1474-81.e2. DOI: 10.1016/j.cgh.2014.01.033. View

Peyrin-Biroulet L, Khosrotehrani K, Carrat F, Bouvier A, Chevaux J, Simon T . Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology. 2011; 141(5):1621-28.e1-5. DOI: 10.1053/j.gastro.2011.06.050. View

Harbord M, Eliakim R, Bettenworth D, Karmiris K, Katsanos K, Kopylov U . Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management. J Crohns Colitis. 2017; 11(7):769-784. DOI: 10.1093/ecco-jcc/jjx009. View

Sandborn W, Feagan B, Rutgeerts P, Hanauer S, Colombel J, Sands B . Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2013; 369(8):711-21. DOI: 10.1056/NEJMoa1215739. View

Sterne J, Savovic J, Page M, Elbers R, Blencowe N, Boutron I . RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019; 366:l4898. DOI: 10.1136/bmj.l4898. View

DHaens G . Risks and benefits of biologic therapy for inflammatory bowel diseases. Gut. 2007; 56(5):725-32. PMC: 1942157. DOI: 10.1136/gut.2006.103564. View

10.

Wenzl H, Primas C, Novacek G, Teml A, Offerlbauer-Ernst A, Hogenauer C . Withdrawal of long-term maintenance treatment with azathioprine tends to increase relapse risk in patients with Crohn's disease. Dig Dis Sci. 2014; 60(5):1414-23. DOI: 10.1007/s10620-014-3419-5. View

11.

Bouhnik Y, Lemann M, Mary J, Scemama G, Tai R, Matuchansky C . Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet. 1996; 347(8996):215-9. DOI: 10.1016/s0140-6736(96)90402-x. View

12.

Chauvin A, Le Thuaut A, Belhassan M, Le Baleur Y, Mesli F, Bastuji-Garin S . Infliximab as a bridge to remission maintained by antimetabolite therapy in Crohn's disease: A retrospective study. Dig Liver Dis. 2014; 46(8):695-700. DOI: 10.1016/j.dld.2014.04.012. View

13.

Chaparro M, Donday M, Barreiro-de Acosta M, Domenech E, Esteve M, Garcia-Sanchez V . Anti-tumour necrosis factor discontinuation in inflammatory bowel disease patients in remission: study protocol of a prospective, multicentre, randomized clinical trial. Therap Adv Gastroenterol. 2022; 12:1756284819874202. PMC: 8832302. DOI: 10.1177/1756284819874202. View

14.

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6(7):e1000097. PMC: 2707599. DOI: 10.1371/journal.pmed.1000097. View

15.

Lobel E, Korelitz B, Xuereb M, Panagopoulos G . A search for the optimal duration of treatment with 6-mercaptopurine for ulcerative colitis. Am J Gastroenterol. 2004; 99(3):462-5. DOI: 10.1111/j.1572-0241.2004.04104.x. View

16.

Ben-Horin S, Chowers Y, Ungar B, Kopylov U, Loebstein R, Weiss B . Undetectable anti-TNF drug levels in patients with long-term remission predict successful drug withdrawal. Aliment Pharmacol Ther. 2015; 42(3):356-64. DOI: 10.1111/apt.13268. View

17.

Beaugerie L, Brousse N, Bouvier A, Colombel J, Lemann M, Cosnes J . Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009; 374(9701):1617-25. DOI: 10.1016/S0140-6736(09)61302-7. View

18.

Qiu Y, Mao R, Chen B, Zhang S, Guo J, He Y . Effects of Combination Therapy With Immunomodulators on Trough Levels and Antibodies Against Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Disease: A Meta-analysis. Clin Gastroenterol Hepatol. 2017; 15(9):1359-1372.e6. DOI: 10.1016/j.cgh.2017.02.005. View

19.

Kennedy N, Heap G, Green H, Hamilton B, Bewshea C, Walker G . Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study. Lancet Gastroenterol Hepatol. 2019; 4(5):341-353. DOI: 10.1016/S2468-1253(19)30012-3. View

20.

Dignass A, Eliakim R, Magro F, Maaser C, Chowers Y, Geboes K . Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis. 2012; 6(10):965-90. DOI: 10.1016/j.crohns.2012.09.003. View